
|Videos|January 20, 2023
Neoadjuvant Treatment of HER2+ Early Breast Cancer
A review of the standard of care regimens for the preoperative or neoadjuvant treatment of HER2+ early breast cancer.
Advertisement
Episodes in this series

Advertisement
Related to this article

The top 5 OncLive TV videos of the week cover insights in NSCLC, HER2+ gastroesophageal cancer, low-grade glioma, HR+ breast cancer, and CML.

The FDA approved giredestrant plus everolimus in ESR1-mutated breast cancer and neladalkib in ALK+ NSCLC, issued a CRL to ivonescimab, and more.

Experts weigh in on standout breast cancer, lung cancer, melanoma, and kidney cancer data presented at the 2026 ESMO Congress.

The FDA approved giredestrant plus everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer.

The top 5 OncLive TV videos of the week cover insights in HER2+ breast cancer, NSCLC, ovarian cancer, prostate cancer, and sarcoma.

The FDA approved pimicotinib for tenosynovial giant cell tumor, accepted a gedatolisib filing in advanced breast cancer, and more.
Advertisement
Advertisement
Trending on OncLive
1
Daraxonrasib Plus Gemcitabine/Nab-Paclitaxel Generates Durable Responses in First-Line Metastatic PDAC
2
The OncFive: Top Oncology Articles for the Week of 11/15
3
TroFuse-015 Meets Primary OS End Point With Sac-TMT in Third-Line or Later Gastroesophageal Adenocarcinoma
4
Dr Iyengar on Oral SERD Implementation in Early-Stage HR+ Breast Cancer
5






